Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06835803 · ClinicalTrials.gov registry record · Phase 2
Enhanced Local Intensified Radiation Therapy in Elderly Glioblastoma: A Phase 2 Hybrid Randomized Trial
A Phase 2 study of Glioblastoma (GBM), sponsored by Brigham and Women's Hospital.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 56
- Enrollment target
- 3
- Study locations
NCT06835803: Recruiting Phase 2 study of Glioblastoma (GBM), sponsored by Brigham and Women's Hospital.
NCT06835803 is a Phase 2 study of Glioblastoma (GBM) that is actively recruiting participants, run by Brigham and Women's Hospital. The registered enrollment target is 56 participants, below the 79-participant average among 7 other Glioblastoma (GBM) trials with a reported enrollment target (29% lower). The trial reports 3 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06835803, a Phase 2 study of Glioblastoma (GBM), is actively recruiting participants, sponsored by Brigham and Women's Hospital.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 56 participants
- Enrollment target
- 3
- Study locations
Study Summary
Glioblastoma (GBM) is an aggressive malignancy of the central nervous system. Older adults with GBM have a unique constellation of medical, psychosocial, and supportive care needs. To address these challenges, prior work has evaluated the feasibility of hypofractionation, a treatment approach delivering fewer, larger radiation dosages over a shorter time period. Common hypofractionated regimens deliver a lower biologically equivalent radiation dose than the conventional regimens used for younger adults. Whether dose escalated hypofractionation can further improve outcomes in older adults remains unclear. This will be a hybrid randomized control trial comparing the efficacy and safety of dose-escalated and standard hypofractionated radiotherapy among older adults with newly-diagnosed glioblastoma compared to standard three-week course. This research study involves the administration of radiation therapy. Radiation will either be delivered at the standard daily dose or at an increased daily dose over a three weeks course of radiation treatment. Research study procedures will include a screening evaluation to assess eligibility, as well as clinical visits for radiation delivery and to assess symptoms during treatment and at scheduled follow-up times. Participants will be randomly assigned to one of the two arms of the trial: 1. Standard hypofractionated radiation over 3 weeks 2. Dose-escalated hypofractionated radiation over 3 weeks
Primary Outcome
through study completion, an average of 1 year
Conditions Studied
Interventions
- RADIATION Dose-escalated radiation therapy
- RADIATION Standard hypofractionated radiation
Study Locations (3)
Massachusetts
- Brigham and Women's Hospital - Boston
- Dana-Farber Brigham Cancer Center, Milford Hospital - Milford
- Dana-Farber Brigham Cancer Center, South Shore Hospital - South Weymouth
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2025-04-14 |
| Est. Completion | 2029-03-31 |
| Phase | Phase 2 |
What NCT06835803 shows while recruiting
NCT06835803 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 56 participants, a relatively small participant target, below the 79-participant average among 7 other Glioblastoma (GBM) trials with a reported enrollment target (29% lower).
The record links to 1 condition, with Glioblastoma (GBM) appearing as the primary indexed condition, and to 2 interventions - of which Dose-escalated radiation therapy is the first listed.
NCT06835803 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06835803 about?
NCT06835803 is a clinical study titled "Enhanced Local Intensified Radiation Therapy in Elderly Glioblastoma: A Phase 2 Hybrid Randomized Trial". Glioblastoma (GBM) is an aggressive malignancy of the central nervous system. Older adults with GBM have a unique constellation of medical, psychosocial, and supportive care needs. To address these challenges, prior work has evaluated the feasibility of hypofractionation, a treatment approach delive...
What is the current status of trial NCT06835803?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 56 participants. The study started on 2025-04-14. Estimated completion is 2029-03-31.
What conditions does trial NCT06835803 study?
This clinical trial studies the following conditions: Glioblastoma (GBM).
What interventions are being tested in trial NCT06835803?
The interventions under investigation include: Dose-escalated radiation therapy (RADIATION), Standard hypofractionated radiation (RADIATION).
Who is sponsoring clinical trial NCT06835803?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06835803 being conducted?
This trial has 3 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma (GBM)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
G-CSF After Chemo-radiation in Patients With Glioblastoma
RECRUITING · Phase 2
-
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
RECRUITING · Phase 2
-
DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)
RECRUITING · Phase 2
-
A Phase 0/1 Clinical Trial With an Expansion Phase of GSK5764227, a B7-H3-Targeted Antibody-Drug Conjugate (ADC), in Patients With Recurrent Grade 4 Glioma and Patients With Brain Metastases
RECRUITING · Early Phase 1
-
Study of Low-Intensity Focused Ultrasound in Combination With Immunotherapy in Newly Diagnosed Unmethylated Glioblastoma
RECRUITING · Phase 1
-
FearLess in NeuroOncology
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02287428 · 56 participants · Phase 1
Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM
- NCT02923011 · 56 participants · Phase 3
Comparative Effectiveness of MRgFUS Versus CTgRFA for Osteoid Osteomas
- NCT02935283 · 56 participants
Neuroimaging and Neuropsychological Outcomes in Urea Cycle Disorders
- NCT03375866 · 56 participants · NA
Effects of Mixed Nut Consumption on Satiety and Weight Management
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI